Source 1review2023Biomedicine & Pharmacotherapy
Toolkit/Exosomes
Exosomes
Also known as: engineered EVs, exosome, extracellular vesicles
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Exosomes possess antigens and immunostimulatory molecules and can serve as cell-free vaccines to induce antitumor immunity. In addition, given their stability, low immunogenicity, and targeting ability, exosomes represent ideal drug delivery systems in tumor immunotherapy.
Usefulness & Problems
Why this is useful
Exosomes are described in the supplied summary as a recurring delivery or communication component in TNBC ncRNA studies. They can carry ncRNA cargo between cells or be used as engineered vesicle-based delivery systems.; ncRNA delivery in TNBC contexts; intercellular transfer of therapeutic or regulatory RNA cargo; Exosomes are described as natural extracellular vesicles used as a nanoplatform for targeted delivery across the blood-labyrinth barrier in sensorineural hearing loss. The review frames them as carriers for nucleic acids, proteins, and small-molecule drugs.; targeted drug delivery for sensorineural hearing loss; overcoming blood-labyrinth barrier delivery constraints; delivery of nucleic acids, proteins, and small-molecule drugs; Exosomes are named as an innovative nanocarrier class discussed for liver disease treatment.; nanocarrier-based liver disease treatment; Exosomes are presented as biological delivery vehicles for CAR-related genetic constructs and as modulators of CAR cell activity. The abstract also states they can function as biosensors.; targeted delivery of genetic constructs; non-viral in vivo CAR cell engineering; modulating CAR cell activity; biosensor functions; Exosomes are named as nanodelivery systems for resveratrol. The review frames them as carriers with potential to improve solubility, biocompatibility, and therapeutic efficacy.; resveratrol delivery; improving solubility; improving biocompatibility; improving therapeutic efficacy; Exosomes are nano-scale extracellular vesicles that transfer biological information from donor cells to tumor immune cells. The abstract describes them as both cell-free vaccines and drug delivery systems in tumor immunotherapy.; cell-free cancer vaccination; delivery of therapeutic cargo in tumor immunotherapy; targeted delivery to tumor cells; Exosomes are small secreted membrane vesicles that transport selected molecular cargo and participate in intercellular signaling. The abstract also notes roles in extracellular matrix remodeling and signal transmission.; therapeutic agent development; intercellular delivery of molecules; cell-to-cell signaling contexts; Exosomes are presented as a subtype of extracellular vesicle that can be transferred to neurons. The review frames them as mediators of supportive or disease-disseminating communication and as possible delivery systems.; neuron-directed intercellular cargo transfer; potential autologous delivery systems; potential biomarker and disease monitoring applications
Source:
Exosomes are described in the supplied summary as a recurring delivery or communication component in TNBC ncRNA studies. They can carry ncRNA cargo between cells or be used as engineered vesicle-based delivery systems.
Source:
ncRNA delivery in TNBC contexts
Source:
intercellular transfer of therapeutic or regulatory RNA cargo
Source:
Exosomes are described as natural extracellular vesicles used as a nanoplatform for targeted delivery across the blood-labyrinth barrier in sensorineural hearing loss. The review frames them as carriers for nucleic acids, proteins, and small-molecule drugs.
Source:
targeted drug delivery for sensorineural hearing loss
Source:
overcoming blood-labyrinth barrier delivery constraints
Source:
delivery of nucleic acids, proteins, and small-molecule drugs
Source:
Exosomes are named as an innovative nanocarrier class discussed for liver disease treatment.
Source:
nanocarrier-based liver disease treatment
Source:
Exosomes are presented as biological delivery vehicles for CAR-related genetic constructs and as modulators of CAR cell activity. The abstract also states they can function as biosensors.
Source:
targeted delivery of genetic constructs
Source:
non-viral in vivo CAR cell engineering
Source:
modulating CAR cell activity
Source:
biosensor functions
Source:
Exosomes are named as nanodelivery systems for resveratrol. The review frames them as carriers with potential to improve solubility, biocompatibility, and therapeutic efficacy.
Source:
resveratrol delivery
Source:
improving solubility
Source:
improving biocompatibility
Source:
improving therapeutic efficacy
Source:
Exosomes are nano-scale extracellular vesicles that transfer biological information from donor cells to tumor immune cells. The abstract describes them as both cell-free vaccines and drug delivery systems in tumor immunotherapy.
Source:
cell-free cancer vaccination
Source:
delivery of therapeutic cargo in tumor immunotherapy
Source:
targeted delivery to tumor cells
Source:
Exosomes are small secreted membrane vesicles that transport selected molecular cargo and participate in intercellular signaling. The abstract also notes roles in extracellular matrix remodeling and signal transmission.
Source:
therapeutic agent development
Source:
intercellular delivery of molecules
Source:
cell-to-cell signaling contexts
Source:
Exosomes are presented as a subtype of extracellular vesicle that can be transferred to neurons. The review frames them as mediators of supportive or disease-disseminating communication and as possible delivery systems.
Source:
neuron-directed intercellular cargo transfer
Source:
potential autologous delivery systems
Source:
potential biomarker and disease monitoring applications
Problem solved
They address the need to move ncRNA-related signals or therapeutics into tumor-relevant biological settings.; providing a delivery or communication vehicle for ncRNA-related therapeutic payloads; They are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.; poor pharmacological access across the blood-labyrinth barrier; need for a biocompatible low-immunogenicity delivery platform; They are presented as part of the nanomedicine toolkit intended to improve therapeutic strategies for liver diseases.; providing an innovative nanocarrier option for liver disease treatment; They are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.; genetic material delivery challenges in CAR therapy; toxicity-related limitations of current CAR-T platforms; They are intended to improve delivery performance of resveratrol, whose clinical efficacy is limited by poor physicochemical and pharmacokinetic properties.; poor resveratrol solubility/permeability; They offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.; providing a cell-free immunotherapy vehicle; delivering RNAs, membrane proteins, chemotherapeutic agents, and immune cell death inducers in tumor immunotherapy; They offer a naturally occurring vesicular route for moving proteins, lipids, and nucleic acids between cells, which motivates their development as therapeutic agents.; providing a naturally derived vesicular platform for transferring molecular cargo between cells; They may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.; provide a vesicle-based route for transfer of molecular cargo to neurons; offer a putative autologous delivery system for neurodegenerative and psychiatric disorders
Source:
They address the need to move ncRNA-related signals or therapeutics into tumor-relevant biological settings.
Source:
providing a delivery or communication vehicle for ncRNA-related therapeutic payloads
Source:
They are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.
Source:
poor pharmacological access across the blood-labyrinth barrier
Source:
need for a biocompatible low-immunogenicity delivery platform
Source:
They are presented as part of the nanomedicine toolkit intended to improve therapeutic strategies for liver diseases.
Source:
providing an innovative nanocarrier option for liver disease treatment
Source:
They are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.
Source:
genetic material delivery challenges in CAR therapy
Source:
toxicity-related limitations of current CAR-T platforms
Source:
They are intended to improve delivery performance of resveratrol, whose clinical efficacy is limited by poor physicochemical and pharmacokinetic properties.
Source:
poor resveratrol solubility/permeability
Source:
They offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.
Source:
providing a cell-free immunotherapy vehicle
Source:
delivering RNAs, membrane proteins, chemotherapeutic agents, and immune cell death inducers in tumor immunotherapy
Source:
They offer a naturally occurring vesicular route for moving proteins, lipids, and nucleic acids between cells, which motivates their development as therapeutic agents.
Source:
providing a naturally derived vesicular platform for transferring molecular cargo between cells
Source:
They may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.
Source:
provide a vesicle-based route for transfer of molecular cargo to neurons
Source:
offer a putative autologous delivery system for neurodegenerative and psychiatric disorders
Problem links
Under-Provisioning of Antibiotics, Vaccines and Other Interventions for Major Global Health Challenges
Gap mapView gapThe summary states that exosomes can function as cell-free vaccines and as drug delivery systems, so they are at least directionally relevant to vaccine and therapeutic development. Their stated stability and low immunogenicity could matter for intervention design.
delivering RNAs, membrane proteins, chemotherapeutic agents, and immune cell death inducers in tumor immunotherapy
LiteratureThey offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.
Source:
They offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.
genetic material delivery challenges in CAR therapy
LiteratureThey are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.
Source:
They are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.
need for a biocompatible low-immunogenicity delivery platform
LiteratureThey are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.
Source:
They are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.
offer a putative autologous delivery system for neurodegenerative and psychiatric disorders
LiteratureThey may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.
Source:
They may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.
poor pharmacological access across the blood-labyrinth barrier
LiteratureThey are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.
Source:
They are proposed to address the delivery barrier imposed by the blood-labyrinth barrier, which hinders pharmacological treatment of sensorineural hearing loss. Their barrier-crossing potential and low immunogenicity are presented as key advantages.
poor resveratrol solubility/permeability
LiteratureThey are intended to improve delivery performance of resveratrol, whose clinical efficacy is limited by poor physicochemical and pharmacokinetic properties.
Source:
They are intended to improve delivery performance of resveratrol, whose clinical efficacy is limited by poor physicochemical and pharmacokinetic properties.
provide a vesicle-based route for transfer of molecular cargo to neurons
LiteratureThey may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.
Source:
They may provide a biologically derived vehicle for moving regulatory cargo in the nervous system and for future therapeutic delivery.
providing a cell-free immunotherapy vehicle
LiteratureThey offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.
Source:
They offer a cell-free way to induce antitumor immunity and to deliver diverse therapeutic cargoes in cancer immunotherapy. The review highlights their stability, low immunogenicity, and targeting ability as reasons they are attractive.
providing a delivery or communication vehicle for ncRNA-related therapeutic payloads
LiteratureThey address the need to move ncRNA-related signals or therapeutics into tumor-relevant biological settings.
Source:
They address the need to move ncRNA-related signals or therapeutics into tumor-relevant biological settings.
providing a naturally derived vesicular platform for transferring molecular cargo between cells
LiteratureThey offer a naturally occurring vesicular route for moving proteins, lipids, and nucleic acids between cells, which motivates their development as therapeutic agents.
Source:
They offer a naturally occurring vesicular route for moving proteins, lipids, and nucleic acids between cells, which motivates their development as therapeutic agents.
providing an innovative nanocarrier option for liver disease treatment
LiteratureThey are presented as part of the nanomedicine toolkit intended to improve therapeutic strategies for liver diseases.
Source:
They are presented as part of the nanomedicine toolkit intended to improve therapeutic strategies for liver diseases.
toxicity-related limitations of current CAR-T platforms
LiteratureThey are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.
Source:
They are proposed to address toxicity, limited specificity, and delivery complexity that constrain broader CAR therapy implementation. They also support non-viral in vivo CAR engineering.
Published Workflows
Objective: Engineer exosome-based delivery systems that can traverse the blood-labyrinth barrier and improve therapeutic efficacy for sensorineural hearing loss.
Why it works: The review frames exosomes as useful because they combine innate biocompatibility and low immunogenicity with the ability to cross biological barriers, while engineering can further improve loading and targeting.
receptor-mediated transcytosisbiological barrier crossingexosome engineeringcargo loading optimizationtargeting enhancementpreclinical evaluationin vivo pharmacokinetic characterization
Stages
- 1.Mechanism and platform selection(decision_gate)
The review first establishes why exosomes are attractive for BLB-limited therapy before discussing engineering refinements.
Selection: Choose exosomes as the delivery platform because of biocompatibility, low immunogenicity, and ability to cross biological barriers including the blood-labyrinth barrier.
- 2.Engineering optimization(library_design)
After selecting exosomes as a promising platform, the review describes engineering as the route to improve payload incorporation and targeting performance.
Selection: Apply engineering strategies to optimize drug loading and enhance targeting.
- 3.Preclinical functional evaluation(functional_characterization)
The review highlights preclinical model evidence as the basis for therapeutic promise after engineering and cargo-delivery design.
Selection: Assess whether engineered exosome cargo delivery can preserve auditory function in preclinical models.
- 4.Translational readiness assessment(decision_gate)
The review explicitly states that these issues remain major barriers to clinical translation despite preclinical promise.
Selection: Evaluate standardization, scalable production, loading efficiency, long-term safety, and in vivo pharmacokinetics before clinical adoption.
Objective: Engineer and evaluate resveratrol nanoformulations that improve delivery performance while reducing safety risk.
Why it works: The review frames nanoencapsulation and formulation optimization as a way to address the physicochemical instability, poor permeability, and rapid metabolism that limit resveratrol efficacy.
nanoencapsulationtargeted deliverycontrolled or improved drug releasenanodelivery system selectionnanoformulation optimizationin vivo testing
Stages
- 1.Nanoformulation design and carrier selection(library_design)
The abstract identifies multiple carrier classes as promising approaches to improve resveratrol delivery performance.
Selection: Choose among nanodelivery system classes for resveratrol nanoencapsulation.
- 2.Formulation optimization(functional_characterization)
The review describes strategies to improve key formulation properties of existing nanoformulations.
- 3.In vivo safety-oriented testing across disease settings(in_vivo_validation)
The abstract explicitly states that in vivo testing is needed to avoid potential safety issues.
Objective: Document specific extracellular vesicle-associated functional activities with sufficient reporting and characterization rigor.
Why it works: The abstract states that specific EV functions should not be assigned from crude, potentially contaminated, heterogeneous preparations alone, and that MISEV2018 provides protocols, steps, and a checklist to document EV-associated functional activities.
distinguishing EV-associated functions from effects attributable to crude, contaminated, or heterogeneous preparationssuggested protocolsstepwise documentationchecklist-based reporting
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
cell-free vaccinationreceptor-mediated transcytosistargeted cargo deliveryTranslation ControlTechniques
No technique tags yet.
Target processes
recombinationtranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
Use of exosomes requires a vesicle source and a way to associate the desired ncRNA cargo with that vesicle context. The supplied payload does not provide protocol-level details.; requires an exosome or EV production and cargo-loading context; review-level payload does not specify manufacturing or targeting requirements in detail; Use in this setting requires exosome engineering strategies for cargo loading and targeting optimization. The review also indicates that scalable production, standardization, and pharmacokinetic characterization are important prerequisites for translation.; requires optimization of drug loading; requires enhancement of targeting; requires refinement of engineering techniques; requires in vivo pharmacokinetic characterization; production scalability; cost-effectiveness; toxicity evaluation; Their use depends on loading or carrying genetic payloads such as mRNA or circular RNA for CAR expression. The abstract frames them as biological delivery vehicles within CAR engineering workflows.; requires payload loading such as mRNA or circular RNA; Use requires exosome-based encapsulation or loading of resveratrol. The abstract does not specify exosome source or loading method.; requires exosome-based loading of resveratrol; Use of exosomes as a therapeutic platform requires isolation and purification workflows and, for delivery applications, methods to load cargo efficiently. Engineered targeting applications also require exosome engineering approaches.; requires isolation and purification methods; requires efficient cargo loading for delivery applications; translation requires larger and longer clinical trials; Use as a therapeutic platform would require access to exosome-producing cells and methods to characterize vesicle cargo and heterogeneity. The abstract does not specify production, purification, or loading methods.; cargo composition is heterogeneous; biogenesis route and vesicle origin may need careful characterization for therapeutic use; Any exosome-based application would require sourcing, isolating, and handling exosomes and their cargo. The abstract specifically mentions autologous exosome-based delivery systems as a therapeutic strategy.; requires exosome source cells such as oligodendrocytes, microglia, or astrocytes for the biological context described; autologous delivery framing implies patient-matched sourcing for some proposed uses
The provided evidence does not establish standardized manufacturing, targeting precision, or safety performance across studies.; the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; The abstract does not support that exosomes alone solve manufacturing, standardization, safety, or clinical translation problems. It explicitly notes unresolved issues in loading efficiency, long-term safety, and scale-up.; standardization challenges; scalable production challenges; loading efficiency challenges; long-term safety remains unresolved; clinical translation remains limited; The abstract does not show that exosomes alone overcome the broader translation barriers of toxicity, scalability, cost, and personalization.; biocompatibility and toxicity concerns; scalability and cost-effectiveness of production; clinical translation limitations; The abstract does not support that exosomes alone overcome the field's technical and translational bottlenecks. It explicitly notes unresolved issues in standardization, cargo loading efficiency, and immature clinical development.; lack of uniform technical standards for isolation and purification; need to improve cargo loading efficiency; clinical trial expansion remains in its infancy; The abstract does not show that exosomes alone solve targeting, manufacturing, or standardization challenges. Their pronounced molecular heterogeneity suggests these remain important limitations.; display pronounced molecular heterogeneity; biogenesis can occur from both plasma and endosome membranes, complicating definition and purity; The abstract does not show that exosome delivery is already clinically validated or that it resolves disease specificity, safety, or efficacy challenges.; therapeutic use is described as putative; the abstract does not specify loading, targeting, or manufacturing methods
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Source 3primary paper2025MED
Source 4review2019Annual Review of Biochemistry
Source 5review2026MED
Source 6review2015Frontiers in Cellular Neuroscience
Source 7review2026PMC
Source 8review2023Drug Delivery
Ranked Claims
Engineered exosomes are reviewed as delivery vehicles for nucleic acids, proteins, and small-molecule drugs in the sensorineural hearing loss context.
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Exosomes are presented as a promising nanoplatform for overcoming blood-labyrinth barrier-limited drug delivery in sensorineural hearing loss.
Engineering strategies for exosomes are described as aiming to optimize drug loading, enhance targeting, and improve therapeutic efficacy for sensorineural hearing loss.
The review states that exosomes can traverse the blood-labyrinth barrier through mechanisms including receptor-mediated transcytosis.
The review highlights that engineered exosomes show potential in preclinical models to preserve auditory function.
Major barriers to clinical translation of exosome-based therapies for sensorineural hearing loss include standardization, scalable production, loading efficiency, long-term safety, and incomplete clinical translation.
Exosomes, virus-like particles, and biomimetic nanostructures are biological nanoparticles with properties that can address key CAR therapy limitations.
These nanoplatforms enable targeted delivery of genetic constructs.
Biological nanoparticle platforms facilitate non-viral in vivo CAR cell engineering and streamline the process compared with conventional ex vivo methods.
Exosomes and biomimetic nanoparticles have versatile cargo capacity for payloads such as mRNA and circular RNA.
These nanoplatforms can mitigate the risk of cytokine release syndrome.
The review focuses on exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms as nanomedicine approaches for liver diseases.
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
The review describes exosomes as attractive for tumor immunotherapy because of stability, low immunogenicity, and targeting ability.
Exosomes are described as drug delivery systems in tumor immunotherapy that can deliver non-coding RNAs, membrane proteins, chemotherapeutic agents, and immune cell death inducers.
Exosomes can be engineered to precisely target tumor cells.
Exosomes can serve as cell-free vaccines that induce antitumor immunity in tumor immunotherapy.
Exosome-based tumor immunotherapy is limited by non-uniform isolation and purification standards, insufficient cargo loading efficiency, and immature clinical translation.
Multiple nanodelivery system classes have shown great potential to improve the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Nanodelivery systems, such as liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, exosomes, macrophages, and red blood cells (RBCs) have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Exosomes are created by budding at both plasma and endosome membranes.
Released exosomes can remodel the extracellular matrix and transmit signals and molecules to other cells.
Exosomes are enriched in selected proteins, lipids, nucleic acids, and glycoconjugates.
Exosomes are small single-membrane secreted organelles approximately 30 to 200 nm in diameter.
diameter ∼30 to ∼200 nm
Exosome-mediated intercellular vesicle traffic plays important roles in development, immunity, tissue homeostasis, cancer, and neurodegenerative diseases.
Exosomes display pronounced molecular heterogeneity.
Exosomes are being developed as therapeutic agents in multiple disease models.
Extracellular vesicles are presented as potential biomarkers and disease monitoring approaches in neurodegenerative and psychiatric disorders.
Specific reference will be made to EVs as potential biomarkers and disease monitoring approaches.
Exosome transfer to neurons is mediated by oligodendrocytes, microglia, and astrocytes and may be supportive or may disseminate disease.
Transfer of exosomes to neurons was shown to be mediated by oligodendrocytes, microglia and astrocytes that may either be supportive to neurons, or instead disseminate the disease.
Extracellular vesicles are key players in intercellular signaling and may carry proteins, mRNAs, and microRNAs.
Evidence is accumulating that secreted extracellular vesicles (EVs), comprising ectosomes and exosomes with a size ranging from 0.1-1 μm, are key players in intercellular signaling. These EVs may carry specific proteins, mRNAs and microRNAs (miRNAs).
Approval Evidence
8 sources24 linked approval claimsfirst-pass slug exosomes
Exosomes, natural extracellular vesicles (30-150 nm), have emerged as a highly promising nanoplatform to overcome this delivery challenge. Their innate biocompatibility, low immunogenicity, and ability to cross biological barriers make them ideal for targeted drug delivery.
Source:
The supplied web research summary states that high-signal mechanistic and therapeutic components repeatedly supported across discovered sources include exosomes/engineered EVs, and related item candidates list exosomes as an explicit delivery/communication component.
Source:
Biological nanoparticles, such as exosomes, virus-like particles, and biomimetic nanostructures, possess unique properties that can address these limitations.
Source:
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
Source:
Exosomes possess antigens and immunostimulatory molecules and can serve as cell-free vaccines to induce antitumor immunity. In addition, given their stability, low immunogenicity, and targeting ability, exosomes represent ideal drug delivery systems in tumor immunotherapy.
Source:
Nanodelivery systems, such as ... exosomes ... have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Source:
On the basis of these and other properties, exosomes are being developed as therapeutic agents in multiple disease models.
Source:
Evidence is accumulating that secreted extracellular vesicles (EVs), comprising ectosomes and exosomes... Transfer of exosomes to neurons was shown to be mediated by oligodendrocytes, microglia and astrocytes... Specific reference will be made to EVs as potential biomarkers and disease monitoring approaches, focusing on their potentialities as drug delivery vehicles, and on putative therapeutic strategies using autologous exosome-based delivery systems.
Source:
delivery modality recurrencesupports
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Source:
delivery rationalesupports
Exosomes are presented as a promising nanoplatform for overcoming blood-labyrinth barrier-limited drug delivery in sensorineural hearing loss.
Source:
mechanism summarysupports
The review states that exosomes can traverse the blood-labyrinth barrier through mechanisms including receptor-mediated transcytosis.
Source:
translation limitationsupports
Major barriers to clinical translation of exosome-based therapies for sensorineural hearing loss include standardization, scalable production, loading efficiency, long-term safety, and incomplete clinical translation.
Source:
capabilitysupports
Exosomes, virus-like particles, and biomimetic nanostructures are biological nanoparticles with properties that can address key CAR therapy limitations.
Source:
delivery functionsupports
These nanoplatforms enable targeted delivery of genetic constructs.
Source:
engineering advantagesupports
Biological nanoparticle platforms facilitate non-viral in vivo CAR cell engineering and streamline the process compared with conventional ex vivo methods.
Source:
payload compatibilitysupports
Exosomes and biomimetic nanoparticles have versatile cargo capacity for payloads such as mRNA and circular RNA.
Source:
safety benefitsupports
These nanoplatforms can mitigate the risk of cytokine release syndrome.
Source:
scope statementsupports
The review focuses on exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms as nanomedicine approaches for liver diseases.
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
Source:
advantage summarysupports
The review describes exosomes as attractive for tumor immunotherapy because of stability, low immunogenicity, and targeting ability.
Source:
delivery rolesupports
Exosomes are described as drug delivery systems in tumor immunotherapy that can deliver non-coding RNAs, membrane proteins, chemotherapeutic agents, and immune cell death inducers.
Source:
engineering potentialsupports
Exosomes can be engineered to precisely target tumor cells.
Source:
functional rolesupports
Exosomes can serve as cell-free vaccines that induce antitumor immunity in tumor immunotherapy.
Source:
limitation summarysupports
Exosome-based tumor immunotherapy is limited by non-uniform isolation and purification standards, insufficient cargo loading efficiency, and immature clinical translation.
Source:
review summarysupports
Multiple nanodelivery system classes have shown great potential to improve the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Nanodelivery systems, such as liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, exosomes, macrophages, and red blood cells (RBCs) have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Source:
biogenesissupports
Exosomes are created by budding at both plasma and endosome membranes.
Source:
biological functionsupports
Released exosomes can remodel the extracellular matrix and transmit signals and molecules to other cells.
Source:
compositionsupports
Exosomes are enriched in selected proteins, lipids, nucleic acids, and glycoconjugates.
Source:
descriptive propertysupports
Exosomes are small single-membrane secreted organelles approximately 30 to 200 nm in diameter.
Source:
Comparisons
Source-stated alternatives
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.; The supplied abstract does not name specific alternative delivery platforms. It only contrasts exosome-based delivery with the broader problem of conventional pharmacological treatment being hindered by the blood-labyrinth barrier.; The abstract lists liposomes, microneedle technologies, biomimetic microfibers, and other emerging platforms alongside exosomes.; The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.; Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.; The abstract contrasts exosome-based approaches with broader cancer immunotherapy, which still faces severe side effects and limited efficacy. No specific alternative delivery platform is named in the abstract.; The supplied evidence places exosomes within the broader extracellular vesicle space and notes related distinctions from microvesicles/ectosomes in the surrounding metadata scaffold, but the abstract itself does not directly compare therapeutic performance against alternatives.; The abstract contrasts exosomes with ectosomes as EV subtypes and discusses broader EVs as the umbrella class.
Source:
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Source:
The supplied abstract does not name specific alternative delivery platforms. It only contrasts exosome-based delivery with the broader problem of conventional pharmacological treatment being hindered by the blood-labyrinth barrier.
Source:
The abstract lists liposomes, microneedle technologies, biomimetic microfibers, and other emerging platforms alongside exosomes.
Source:
The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.
Source:
Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.
Source:
The abstract contrasts exosome-based approaches with broader cancer immunotherapy, which still faces severe side effects and limited efficacy. No specific alternative delivery platform is named in the abstract.
Source:
The supplied evidence places exosomes within the broader extracellular vesicle space and notes related distinctions from microvesicles/ectosomes in the surrounding metadata scaffold, but the abstract itself does not directly compare therapeutic performance against alternatives.
Source:
The abstract contrasts exosomes with ectosomes as EV subtypes and discusses broader EVs as the umbrella class.
Source-backed strengths
repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility; low immunogenicity; ability to cross biological barriers; supports diverse cargo classes; programmability; versatile cargo capacity; presented as a promising biological nanocarrier for resveratrol; stability; targeting ability; can carry antigens and immunostimulatory molecules; carry selected proteins, lipids, nucleic acids, and glycoconjugates; naturally participate in intercellular traffic and signaling; being developed as therapeutic agents in multiple disease models; explicitly described as transferred to neurons; highlighted as a putative autologous delivery system
Source:
repeatedly supported across multiple TNBC-related sources in the supplied summary
Source:
treated as a delivery and communication component rather than only a biological phenomenon
Source:
innate biocompatibility
Source:
low immunogenicity
Source:
ability to cross biological barriers
Source:
supports diverse cargo classes
Source:
innate biocompatibility
Source:
programmability
Source:
versatile cargo capacity
Source:
presented as a promising biological nanocarrier for resveratrol
Source:
stability
Source:
low immunogenicity
Source:
targeting ability
Source:
can carry antigens and immunostimulatory molecules
Source:
carry selected proteins, lipids, nucleic acids, and glycoconjugates
Source:
naturally participate in intercellular traffic and signaling
Source:
being developed as therapeutic agents in multiple disease models
Source:
explicitly described as transferred to neurons
Source:
highlighted as a putative autologous delivery system
Compared with antisense oligonucleotide
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Compared with anti-sense oligonucleotides
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Compared with antisense oligonucleotides
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Compared with extracellular vesicles
The supplied evidence places exosomes within the broader extracellular vesicle space and notes related distinctions from microvesicles/ectosomes in the surrounding metadata scaffold, but the abstract itself does not directly compare therapeutic performance against alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The supplied evidence places exosomes within the broader extracellular vesicle space and notes related distinctions from microvesicles/ectosomes in the surrounding metadata scaffold, but the abstract itself does not directly compare therapeutic performance against alternatives.
Compared with lipid nanoparticles
Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.
Compared with polymeric micelles
Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
Alternatives named in the abstract include liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, macrophages, and RBCs.
Compared with small interfering RNA
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The supplied summary also names nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides as adjacent therapeutic or delivery approaches.
Compared with virus-like particles
The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.
Compared with virus-like particle vaccine platform
The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.
Shared frame: source-stated alternative in extracted literature
Strengths here: repeatedly supported across multiple TNBC-related sources in the supplied summary; treated as a delivery and communication component rather than only a biological phenomenon; innate biocompatibility.
Relative tradeoffs: the anchor review text itself was not provided, so specific comparative advantages and liabilities are not directly recoverable here; standardization challenges; scalable production challenges.
Source:
The abstract contrasts exosomes with virus-like particles and biomimetic nanostructures as other biological nanoparticle platforms.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.